Medical-device maker Medtronic in talks to buy Irish rival

Jun 15, 2014

US medical-device maker Medtronic is in advanced talks to buy competitor Covidien, based in Ireland, for more than $40 billion, The Wall Street Journal reported Saturday.

The deal, which could be announced Monday, would allow Medtronic to take advantage of Ireland's lower business tax rates—12.5 percent versus 35 percent in the United States—in a process known as "tax inversion," the newspaper reported, citing people familiar with the matter.

According to the paper, the talks are well under way, but could still hit snags at the last minute.

A number of US companies, in particular in the , have recently launched bids to buy companies as a way to reduce their costs and tax burden and use their cash overseas.

Pfizer recently abandoned an attempt to buy British firm AstraZeneca for $117 billion in a deal that would have allowed the US company to take advantage of Britain's lower corporate tax rate.

The United States is considering amending its legislation to allow multinational companies to keep overseas indefinitely a portion of their profits in order to avoid paying US taxes on it.

Based in the midwestern US city of Minneapolis, Medtronic makes orthopedic and cardiovascular devices and is valued at around $61 billion, compared to Covidien's $32 billion. Covidien develops devices used in surgery, the Journal said.

Explore further: Google eyeing up to $30 billion in foreign buyouts

add to favorites email to friend print save as pdf

Related Stories

AstraZeneca fends off Pfizer with new growth plan

May 06, 2014

AstraZeneca on Tuesday outlined plans to make sales jump over the next decade, an effort to persuade shareholders the drug maker can do well as an independent company, rather than get bought out by rival ...

Recommended for you

Sony forecasts $2B loss as smartphones lag (Update)

14 hours ago

Sony expects its annual loss to swell to $2 billion and has canceled dividends for the first time in more than half a century after writing down the value of its troubled smartphone business.

Alibaba post-IPO structure gives insiders control

14 hours ago

Control over Alibaba Group will stay in the hands of founder Jack Ma and other company veterans after the Chinese e-commerce giant goes public on the New York Stock Exchange in a record busting share sale.

User comments : 2

Adjust slider to filter visible comments by rank

Display comments: newest first

BSD
not rated yet Jun 15, 2014
Finance, not science.
ryggesogn2
5 / 5 (1) Jun 16, 2014
Finance, not science.


That's why this story is in the Technology/Business section.